These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37603221)

  • 1. The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer.
    Demir AN; Kara Z; Sulu C; Uysal S; Zulfaliyeva G; Atar OA; Valikhanova N; Ozturk T; Ozkaya HM; Damci T; Gonen MS
    Hormones (Athens); 2023 Dec; 22(4):595-602. PubMed ID: 37603221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone-Marrow Suppression in Elderly Patients Following Empiric Radioiodine Therapy: Real-Life Data.
    Duskin-Bitan H; Leibner A; Amitai O; Diker-Cohen T; Hirsch D; Benbassat C; Shimon I; Robenshtok E
    Thyroid; 2019 May; 29(5):683-691. PubMed ID: 31084551
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment.
    Yi W; Kim BH; Kim M; Ryang SR; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
    Endocr J; 2020 Dec; 67(12):1193-1198. PubMed ID: 32727965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer.
    Hu T; Meng Z; Zhang G; Jia Q; Tan J; Zheng W; Wang R; Li X; Liu N; Zhou P; Upadhyaya A
    Medicine (Baltimore); 2016 Aug; 95(35):e4451. PubMed ID: 27583853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy.
    Dong P; Wang L; Huang R; Li L
    Medicine (Baltimore); 2020 Jul; 99(31):e21398. PubMed ID: 32756134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation.
    Molinaro E; Leboeuf R; Shue B; Martorella AJ; Fleisher M; Larson S; Tuttle RM
    Thyroid; 2009 Oct; 19(10):1035-41. PubMed ID: 19772430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Long-Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine.
    Sönmez B; Bektaş Ö; Erkut N; Sönmez M
    Turk J Haematol; 2021 Dec; 38(4):306-313. PubMed ID: 33749216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
    Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
    Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
    van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
    Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
    [No Abstract]   [Full Text] [Related]  

  • 10. Temporary changes in neutrophil-to-lymphocyte, platelet-to-lymphocyte ratios, and mean platelet volume reflecting the inflammatory process after radioiodine therapy.
    Demir Y; Üçler R; Sürücü E; Turan M; Balli Z; Şengöz T
    Nucl Med Commun; 2016 Apr; 37(4):393-8. PubMed ID: 26619396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer.
    Padovani RP; Tuttle RM; Grewal R; Larson SM; Boucai L
    Endocr Pract; 2014 Mar; 20(3):213-20. PubMed ID: 24126230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
    Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
    Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
    Chow SM; Yau S; Lee SH; Leung WM; Law SC
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 19. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of radioactive iodine therapy on liver function in patients with differentiated thyroid cancer.
    Wang S; Liang C; Zhao L; Meng Z; Zhang C; Jia Q; Tan J; Yang H; Liu X; Wang X
    Nucl Med Commun; 2018 Dec; 39(12):1113-1120. PubMed ID: 30247387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.